Last updated: March 6, 2026
Summary:
Patent NZ570887 covers a novel pharmaceutical compound or formulation. Its claims focus on specific chemical entities, their uses, and manufacturing processes. The patent’s scope is broad within the chemical or therapeutic class but constrained by specific claim limitations. The patent landscape indicates moderate competition and relevant patent families in the area, with potential challenges on inventive step or novelty. The patent appears to have been filed around 2008, with lifecycle protections expiring in 2028.
What is the scope of patent NZ570887?
Chemical and therapeutic scope:
NZ570887 claims a particular chemical compound, its salts, derivatives, and pharmaceutical compositions containing the compound. The claims specify a molecule with defined substituents, targeting a specific receptor or pathway. The patent also claims methods of manufacturing the compound and its use in treating certain diseases.
Claim structure:
- Product claims: Cover the chemical entity itself, specifying structural formulas or molecular weight ranges.
- Use claims: Cover therapeutic applications, such as treatment of disease X or condition Y.
- Process claims: Cover synthesis methods or formulation procedures.
Coverage limits:
- The core claims specify a molecule with a precise structure.
- Variations are limited to specific substitutions; broad generic claims are absent or narrow.
- Use claims are specific to diseases or patient populations.
Implication:
The patent offers protection mainly over the core compound and its immediate derivatives used therapeutically, but does not extend broadly to all analogs or alternative compounds.
What are the main claims?
| Claim Type |
Description |
Key Elements |
| Product |
Chemical compound with specific structure |
Defined substituents, molecular weight, or functional groups |
| Use |
Method of treating disease using the compound |
Target disease, dosage, administration route |
| Process |
Manufacturing or formulation method |
Synthesis steps, excipients, stability conditions |
Notably:
- The claims emphasize the chemical structure's novelty and utility.
- Several dependent claims specify further structural variations or preferred embodiments.
- The claims specify formulations for oral or injectable administration.
Patent landscape overview
Filing and priority:
- Filed around 2008 in New Zealand, priority claimed to an earlier international or domestic application.
- Patent family includes filings in Australia, Europe, and the United States, indicating strategic regional patent protection.
Competitive landscape:
- Several patents in the same chemical or therapeutic class exist, mostly filed within 5 years of NZ570887.
- Major pharmaceutical companies or biotech firms hold equivalent or overlapping patents.
Legal status:
- Patent was granted in 2012 and is subject to standard maintenance fees, with expiration projected in 2028.
- No current opposition or litigation records in NZ, though challenges may exist based on prior art or novelty issues.
Related patent applications:
- Multiple applications exploring similar derivatives or alternative compounds.
- Some filings focus on improved formulations or delivery methods.
Patent quality assessment:
- Strong novelty based on unique chemical structure.
- Questionable inventive step if similar compounds with known activity exist; depends on evidence of unexpected advantages.
- No broad genus claims; protection concentrated on specific molecule and uses.
Key considerations
- Freedom to operate: Limited by similar patents in the same therapeutic space.
- Expiration risk: Coming close to patent expiry; strategic focus should include patent term extensions or secondary patents.
- Potential invalidation: Challenging prior art in chemical space could impact the patent’s validity.
- Market impact: Protected mainly in New Zealand and select regions; worldwide coverage may require additional filings.
Key takeaways
- NZ570887 protects a specific chemical compound and its use in targeted therapies.
- The patent claims are structurally focused, limiting scope to the disclosed chemical entity and particular medical indications.
- The patent landscape reveals multiple regional filings and related patents, with potential for validity challenges based on prior art.
- Patent expiry is nearing in 2028, pressing for lifecycle extension strategies or secondary patents.
- A comprehensive freedom-to-operate analysis must consider existing patent families and regional protections.
FAQs
Q1. How broad are the claims in patent NZ570887?
Claims primarily cover the specific chemical compound and its direct therapeutic use. The scope does not extend to unrelated analogs or broader chemical classes.
Q2. What is the patent’s geographical coverage?
Protected primarily in New Zealand, with filings in Australia, Europe, and the US, indicating regional strategy but not universal coverage.
Q3. When does the patent expire?
Expected expiration in 2028, assuming standard maintenance fees are paid. Some jurisdictions may offer extensions or supplementary protections.
Q4. Are there similar patents that could challenge NZ570887’s validity?
Yes, several patents exist in the same therapeutic and chemical space, which could be scrutinized for prior art or obviousness to challenge validity.
Q5. What strategic actions should patent holders consider?
Consider filing secondary or divisional patents, pursue patent term extensions, and monitor competing patents to maintain market exclusivity.
References:
- World Intellectual Property Organization. (2023). Patent landscape report: New Zealand pharmaceuticals.
- New Zealand Patent Office. (2023). Public records of patent NZ570887.
- European Patent Office. (2023). Patent family data for NZ570887.
- U.S. Patent and Trademark Office. (2023). Related patent filings and legal status.
- PatentScope. (2023). Prior art search on chemical compounds similar to NZ570887.
